Dr. David Moller is based in Boston and has extensive experience in biopharmaceutical R&D. He currently serves as Chief Scientific Officer at Sigilon Therapeutics, a biotechnology company developing a new class of medicines which employs engineered cells for the treatment of chronic diseases – including hemophilia and lysosomal storage diseases.
David has 20 years of prior experience leading R&D efforts at Merck and Eli Lilly where he focused on cardiometabolic, endocrine and musculoskeletal disorders. His team discovered and developed several products including Januvia and Trulicity.
David holds an M.D. from the University of Cincinnati and completed clinical and research training programs at the George Washington and Harvard Universities. He also served on the Harvard faculty for several years where his laboratory discovered key mechanisms underlying the pathogenesis of metabolic disorders.
David has published more than 130 peer-reviewed papers. His honors include election to the American Society of Clinical Investigation, the Association of American Physicians, and appointment as an adjunct professor at the Karolinska Institute